1201-74-7Relevant articles and documents
Resolution of 1-arylethylamines with 5-(1,2-O-isopropylidene-3,6-anhydro- α-D-glucofuranosyl) hydrogen phthalate
Mereyala, Hari Babu,Pola, Pallavi
, p. 2683 - 2685 (2003)
The potential of the hydrogen phthalate of 1,2-O-isopropylidene-3,6- anhydro-α-D-glucofuranose 1 obtainable by the reaction of phthalic anhydride with 1,2-O-isopropylidene-3,6-anhydro-α-D-glucofuranose 8 as a new resolving agent is shown. The salts between 1 and (RS)-1-arylethylamines 2-6 and (RS)-1-arylpropylamine 7 selectively crystallize 1·(R)-salts allowing the recovery of the corresponding (R)-amines 2-7. The more soluble 1·(S)-salts were analogously processed to obtain (S)-amines, respectively. In all of the cases (R)- and (S)-amines 2-7 were obtained in high chemical yield and enantiomeric excess >98%. Resolving agent 1 has been recovered in a quantitative yield and high purity.
Synthesis and structures of chiral halo mercury(II) complexes
Guel, Nizamettin,Nelson, John H.
, p. 121 - 130 (1999)
HgCl2 reacts with enantiomerically pure 3-lithio-(S)-(-) or (R)-(+)-N,N-dimethyl-α-(2-naphthyl)ethylamine, (S) or (R)-LiTMNA, to produce (S)C(R)Hg-(HgCl), 2a', or (S)C(R)Hg-(HgCl), 2a, in fair yields. The bromide (2b) and iodide (2c) analogs were prepared in good yields by reaction of 2a with NaBr and NaI, respectively. The crystal structures of 2a', 2b and 2c show that the Hg atom in each compound is three-coordinate, T-shaped, and slightly pyramidal in the solid state. These three compounds form exclusively as the (S)C(R)Hg or (R)C(S)Hg diastereomers with average Hg-C and Hg-N distances of 2.08 (2) Angstroem and 2.65 (2) Angstroem, respectively. The Hg-N bond is weak and is easily cleaved in solution to form temperature-dependent equilibrium mixtures of two- and three-coordinate species as deduced from variable temperature NMR spectroscopy. - Keywords: Orthometallation; Mercury; Chiral complexes; CD spectroscopy; X-ray crystallography
-
Menicagli,R. et al.
, p. 1301 - 1306 (1979)
-
Iterative Alanine Scanning Mutagenesis Confers Aromatic Ketone Specificity and Activity of L-Amine Dehydrogenases
Mu, Xiaoqing,Wu, Tao,Mao, Yong,Zhao, Yilei,Xu, Yan,Nie, Yao
, p. 5243 - 5253 (2021/11/16)
Direct reductive amination of prochiral ketones catalyzed by amine dehydrogenases is attractive in the synthesis of active pharmaceutical ingredients. Here, we report the protein engineering of L-Bacillus cereus amine dehydrogenase to allow reactivity on synthetically useful aromatic ketone substrates using an iterative, multiple-site alanine scanning mutagenesis approach. Mutagenesis libraries based on molecular docking, iterative alanine scanning, and double-proximity filter approach significantly expand the scope of active pharmaceutical ingredients relevant building blocks. The eventual quintuple mutant (A115G/T136A/L42A/V296A/V293A) showed reactivity toward aromatic ketones 12 a (5-phenyl-pentan-2-one) and 13 a (6-phenyl-hexan-2-one), which have not been reported to serve as targets of reductive amination by currently available amine dehydrogenases. Docking simulation and tunnel analysis provided valuable insights into the source of the acquired specificity and activity.
Air Stable Iridium Catalysts for Direct Reductive Amination of Ketones
Polishchuk, Iuliia,Sklyaruk, Jan,Lebedev, Yury,Rueping, Magnus
supporting information, p. 5919 - 5922 (2021/03/08)
Half-sandwich iridium complexes bearing bidentate urea-phosphorus ligands were found to catalyze the direct reductive amination of aromatic and aliphatic ketones under mild conditions at 0.5 mol % loading with high selectivity towards primary amines. One of the complexes was found to be active in both the Leuckart–Wallach (NH4CO2H) type reaction as well as in the hydrogenative (H2/NH4AcO) reductive amination. The protocol with ammonium formate does not require an inert atmosphere, dry solvents, as well as additives and in contrast to previous reports takes place in hexafluoroisopropanol (HFIP) instead of methanol. Applying NH4CO2D or D2 resulted in a high degree of deuterium incorporation into the primary amine α-position.
HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS
-
Paragraph 0265-0266, (2020/07/16)
The present disclosure relates generally to compounds useful in treatment of conditions associated with mutant isocitrate dehydrogenase (mt-IDH), particularly mutant IDH1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against mutant IDH1 enzymes. Method of treating conditions associated with excessive activity of mutant IDH1 enzymes with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.